Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma (Q37355035)

19 August 2017

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6600883

24 December 2023

author name string

H. Ulrich-Pur

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

M. Raderer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

G. Verena Kornek

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

B. Schüll

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

K. Schmid

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

K. Haider

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

W. Kwasny

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

D. Depisch

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

B. Schneeweiss

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

F. Lang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

W. Scheithauer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

24 December 2023

language of work or name

English

0 references

publication date

1 April 2003

1 reference

PMCID

2747555

19 August 2017

22 April 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12698181

full work available at URL

24 December 2023

https://doi.org/10.1038/sj.bjc.6600883

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

https://europepmc.org/articles/PMC2747555

24 December 2023

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

https://europepmc.org/articles/PMC2747555?pdf=render

24 December 2023

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12698181

http://www.nature.com/articles/6600883.pdf

24 December 2023

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1038/SJ.BJC.6600883

http://www.nature.com/articles/6600883

24 December 2023

1 reference

DOI

https://api.crossref.org/works/10.1038/SJ.BJC.6600883

British Journal of Cancer

24 December 2023

published in

1 reference

19 August 2017

88

1 reference

19 August 2017

8

1 reference

19 August 2017

1180-1184

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600883

19 August 2017

0 references

cites work

Raltitrexed: current clinical status and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Gemcitabine-based combination treatment of pancreatic cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Reporting results of cancer treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Chemotherapy of adenocarcinoma of the pancreas

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Optimal two-stage designs for phase II clinical trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

2 September 2018

Cancer statistics, 1996.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747555

Some Methods for Strengthening the Common χ 2 Tests

2 September 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600883

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600883

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12698181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12698181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12698181

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

1 reference

19 August 2017

1 reference

19 August 2017

1 reference

PMCID

2747555